Structure Therapeutics (GPCR) to Announce Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.39) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. On average, analysts expect Structure Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Structure Therapeutics Trading Up 0.5%

Structure Therapeutics stock traded up $0.27 during mid-day trading on Tuesday, hitting $48.62. The company had a trading volume of 37,471 shares, compared to its average volume of 897,204. Structure Therapeutics has a 12-month low of $15.80 and a 12-month high of $94.90. The company’s fifty day moving average is $46.69 and its 200-day moving average is $54.94. The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of -55.89 and a beta of -1.50.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. HC Wainwright dropped their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Canaccord Genuity Group started coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.55.

Institutional Trading of Structure Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. HighTower Advisors LLC grew its holdings in shares of Structure Therapeutics by 3.6% during the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock worth $648,000 after buying an additional 320 shares in the last quarter. State of Wyoming lifted its stake in shares of Structure Therapeutics by 29.7% in the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after buying an additional 403 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in Structure Therapeutics by 14.5% during the third quarter. Envestnet Asset Management Inc. now owns 12,220 shares of the company’s stock worth $342,000 after acquiring an additional 1,544 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in Structure Therapeutics during the fourth quarter worth about $127,000. Finally, State Street Corp lifted its stake in Structure Therapeutics by 4.8% in the 4th quarter. State Street Corp now owns 48,224 shares of the company’s stock worth $3,354,000 after purchasing an additional 2,207 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.